Recently published research from Business Monitor International, "Zimbabwe Pharmaceuticals & Healthcare Report Q4 2012", is now available at Fast Market Research
Boston, MA -- (SBWIRE) -- 01/23/2013 -- BMI View: Regardless of the outcome of the upcoming general elections, scheduled for November 2012, we remain pessimistic about the short- to medium-term development of Zimbabwe's pharmaceutical market. While the need for medicines is vast, the majority of demand continues to be met through foreign donations, indicating the dire situation in the country. At the same time, the domestic industry continues to struggle, without much hope for government finances or credit extensions, which will continue to exacerbate the already massive problems with regard to access to medicines.
Headline Expenditure Projections
- Pharmaceuticals: US$160mn in 2011 to US$180mn in 2012; +12.7% in US dollar terms. Forecast in line with Q312.
- Healthcare US$833mn in 2011 to US$919mn in 2012; +10.3% in US dollar terms. Forecast unchanged from Q312.
- Medical devices: US$44mn in 2011 to US$49mn in 2012; +10.4% in US dollar terms. Forecast unchanged from Q312.
Risk/Reward Rating: In BMI's Pharmaceutical Risk/Rewards Ratings (RRRs) table for Q412, Zimbabwe's score is an unchanged 30.1, which again ranks the country 28th of the 30 markets surveyed in the Middle East and Africa (MEA). Zimbabwe will remain one of the least attractive pharmaceutical and healthcare markets regionally and globally (currently ranking 93rd out of 95 countries surveyed) on account of the elevated political, economic and social risks, as well as the lack of finances for adequate healthcare provision and capacity utilisation.
View Full Report Details and Table of Contents
Key Trends And Developments
- In June 2012, the Japanese government funded a week-long immunisation programme in Zimbabwe which aimed to vaccinate 2mn children against polio and measles, as well as provide vitamin A supplements. The campaign is part of Zimbabwe's attempts to reduce child mortality in the country. The Japanese government offered the financial assistance to UNICEF rather than to the Zimbabwean government, over fears of corruption. UNICEF, via support from Japan and the Zimbabwean Ministry of Health, has managed to increase access to measles and polio vaccines, injections and safety materials, said UNICEF chief of health Peter Salama.
- The Health Transition Fund, established by Zimbabwean Prime Minister Morgan Tsvangirai in 2011, is showing positive results as partners have released money to reduce the number of maternal deaths. The fund was launched to raise more than US$400mn by 2016 and raised US$45mn in 2012, with the total budget for the year being US$69mn, said Gerald Gwinji, permanent secretary at the health ministry. The remaining amount will be made available after the programme achieves its targets, Gwinji added.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- United Arab Emirates Pharmaceuticals & Healthcare Report Q4 2012
- India Pharmaceuticals & Healthcare Report Q4 2012
- Lebanon Pharmaceuticals & Healthcare Report Q4 2012
- Cipher Pharmaceuticals Inc. (DND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Egypt Pharmaceuticals & Healthcare Report Q4 2012
- Lithuania Pharmaceuticals & Healthcare Report Q4 2012
- Peru Pharmaceuticals & Healthcare Report Q4 2012
- Singapore Pharmaceuticals & Healthcare Report Q4 2012
- Malaysia Pharmaceuticals & Healthcare Report Q4 2012
- Kuwait Pharmaceuticals & Healthcare Report Q4 2012